Manufacturing News of Note—Colorcon creates VC fund; FDA standardizing assessments; Upperton adds tableting

stocks
(Pixabay)

> Pharma supplier Colorcon has created a $50 million venture capital fund to invest in what a spokesman says would be new manufacturing technologies like track-and-trace systems and artificial intelligence solutions but not in companies that develop APIs or molecules. Release

> The FDA is creating a new system it expects will provide the information about the inherent risk and control approaches for product design, manufacturing and facilities to improve its quality assessments. Story

> Australian CDMO Cell Therapies says it is the first company in Australia to be granted a product class (T cells) GMP manufacturing license by regulators for commercial supply of the cells. Release

> U.K.-based clinical supply CDMO Upperton Pharma Solutions has invested in new tableting capabilities. Release

> French CMO Indicia Production has acquired Bio-Steril, also a French company, which specializes in the formulation and fill and finish of medical devices for medical and cosmetic uses. Release 

> GE Healthcare and the National Institute of Bioprocessing Research and Training in Dublin are working together to create training programs in biopharmaceutical and cell therapy development and manufacturing. Release

> CDMO Pharmaceutics International will manufacturer Sagent Pharmaceuticals' recently approved fulvestrant injection.  Release

 

 

Suggested Articles

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.

The FDA knocked a California compounding pharmacy facility for a suite of sanitary concerns, including the presence of ants in the plant.

Merck Animal Health will plow $100 million into its DeSoto, Kansas, plant to scale up production of animal vaccines.